NORTH CHICAGO, Ill.,
May 14, 2019 /PRNewswire/
-- AbbVie (NYSE: ABBV) announced that it has resolved U.S.
HUMIRA (adalimumab) litigation with Boehringer Ingelheim (BI).
Under the terms of the resolution, AbbVie will grant BI a
non-exclusive license to its HUMIRA-related intellectual property
in the United States. The U.S.
license for BI will begin on July
1, 2023. BI will pay royalties to AbbVie for licensing
its HUMIRA patents and acknowledges the validity and enforceability
of the licensed patents. AbbVie will make no payments of any form
to BI.
"This is an important settlement as it resolves all
HUMIRA-related patent litigation in the U.S and provides access for
another biosimilar manufacturer seeking to enter the U.S.," said
Laura Schumacher, Vice Chairman,
External Affairs and Chief Legal Officer at AbbVie. "As an
innovation-driven biopharmaceutical company, we will continue to
develop novel cures for the toughest health challenges and rely on
a robust patent system to protect that investment in
innovation."
About AbbVie
AbbVie is a global, research-driven
biopharmaceutical company committed to developing innovative
advanced therapies for some of the world's most complex and
critical conditions. The company's mission is to use its expertise,
dedicated people and unique approach to innovation to markedly
improve treatments across four primary therapeutic areas:
immunology, oncology, virology and neuroscience. In more than 75
countries, AbbVie employees are working every day to advance health
solutions for people around the world. For more information about
AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
Twitter, Facebook or LinkedIn.
Forward-Looking Statements
Some statements in this
news release are, or may be considered, forward-looking statements
for purposes of the Private Securities Litigation Reform Act of
1995. The words "believe," "expect," "anticipate," "project" and
similar expressions, among others, generally identify
forward-looking statements. AbbVie cautions that these
forward-looking statements are subject to risks and uncertainties
that may cause actual results to differ materially from those
indicated in the forward-looking statements. Such risks and
uncertainties include, but are not limited to, challenges to
intellectual property, competition from other products,
difficulties inherent in the research and development process,
adverse litigation or government action, and changes to laws and
regulations applicable to our industry. Additional information
about the economic, competitive, governmental, technological and
other factors that may affect AbbVie's operations is set forth in
Item 1A, "Risk Factors," of AbbVie's 2017 Annual Report on Form
10-K, which has been filed with the Securities and Exchange
Commission. AbbVie undertakes no obligation to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
View original
content:http://www.prnewswire.com/news-releases/abbvie-resolves-humira-adalimumab-us-patent-litigation-with-boehringer-ingelheim-300849342.html
SOURCE AbbVie